English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 19 May 2023, 07:00 HKT/SGT
Share:
    

Source: CellOxess Biotechnology
Fertilix Proven Effective in Blocking Damage From Low-Dose Exposure to Chemicals Commonly Found in Plastic Consumer Products

CLERMONT-FERRAND, FRANCE, May 19, 2023 - (ACN Newswire) - According to a recent study by Universite Clermont Auvergne researchers, exposure to chemical additives and building blocks commonly used in everyday plastic products, even in low doses, can cause significant damage to the genetic material carried by sperm cells.

Fertilix(R) logo

The study, led by Professor Joel Drevet, examined two common chemicals widely used in the plastic industry: dibutyl phthalate and bisphenol AF. These chemicals have long been linked to lowering male fertility, but the novelty of this study was in evaluating doses that were previously considered safe or inconsequential for consumers. While researchers found no appreciable effect on general semen parameters typically examined in fertility clinics such as sperm counts and motility, significant oxidation and decompaction of DNA structure in sperm cells were observed. This is concerning because damage to paternal genetic material can expose the female partner to higher risk of pregnancy loss and potentially impact the health of the offspring. Interestingly, the study also showed that co-administration with micronutrient supplement Fertilix(R) significantly blocked the damaging effects of these chemicals on sperm DNA.

Given that microplastics are found everywhere in our surroundings, these findings underscore the importance of greater public awareness and the urgency for the plastic industry to replace such substances with biodegradable or natural alternatives. Furthermore, fertility experts counseling couples ahead of natural or assisted conception should advocate for preconceptual supplementation and possible lifestyle modifications that may mitigate the impact of environmental pollutants.

This study is now available with open-access in Antioxidants, a premier journal in antioxidant research, and can be downloaded here. https://www.mdpi.com/2076-3921/12/5/1046 CellOxess Biotechnology, the designer and manufacturer of Fertilix(R) formulations, will present the full results of this study at the European Society of Human Reproduction and Embryology (ESHRE) annual meeting this June in Copenhagen, Denmark.

Contact Information
Frances Gallagher, MPH
Marketing & Communications Coordinator
contact@celloxess.com

Topic: Press release summary
Source: CellOxess Biotechnology

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Empowering marginalized children to improve standard of living  
July 17, 2024 12:00 HKT/SGT
New Horizons for SMEs in the Johor-Singapore SEZ  
July 17, 2024 12:00 HKT/SGT
Save A Train Presents Another New and Unique Addition to its Expanding Global Rail Platform: Rail Forward!  
July 17, 2024 10:00 HKT/SGT
The Laughing Cow Brings Innovation to Snacking with Delicious Cheez Dippers  
July 17, 2024 10:00 HKT/SGT
Fujitsu-sponsored professional golfer Ayaka Furue victorious in the Amundi Evian Championship  
Tuesday, July 16, 2024 10:26:00 PM
Best BLUETTI Prime Day Deals on Portable Power Stations and Solar Generators  
July 16, 2024 22:00 HKT/SGT
Lexaria Preparing For Strategic Growth  
July 16, 2024 21:20 HKT/SGT
'Alamein Festival' Launches Exciting Second Edition for 2024  
July 16, 2024 21:00 HKT/SGT
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating  
July 16, 2024 20:00 HKT/SGT
How Artificial Intelligence Can Help Give Your Business a Boost  
July 16, 2024 19:30 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575